Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis

Pharmacology and Therapeutics

Volumn 95, Issue 1, 2002, Pages 47-62

  Vosper, Helen ^a   Khoudoli, Guennadi A ^a   Graham, Tracey L ^a   Palmer, Colin N A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Fibrates; Lipid lowering drugs; Lipoproteins; Peroxisome proliferator activated receptors; Thiazolidinediones

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FENOFIBRATE; GELATINASE B; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SCAVENGER RECEPTOR; THROMBOPLASTIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADIPOCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART FUNCTION; HUMAN; HYPERLIPIDEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; DRUG POTENTIATION; METABOLISM;

ANIMAL; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; ANIMALS; HUMANS; HYPERLIPIDEMIAS;

EID: 0035993444     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00232-2     Document Type: Review

References (216)

1. Clofibrate in ischaemic heart disease
2. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region
3. Ischaemic heart disease: A secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians
4. Clofibrate and coronary heart disease
5. Clofibrate and heart disease
6. Clofibrate in the treatment and prevention of ischaemic heart disease: Recent trials
7. Clofibrate and niacin in coronary heart disease
8. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators
9. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Mortality follow-up. Report of the Committee of Principal Investigators
10. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Report of the Committee of Principal Investigators
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers
13. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure
14. The common PPARγPro12Ala polymorphism is associated with decreased risk of type 2 diabetes
15. Cholesterol and mortality. 30 years of follow-up from the Framingham study
16. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease
17. Rosiglitazone
18. PPARγ is required for placental, cardiac, and adipose tissue development
19. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth
20. High-density lipoproteins and coronary heart disease
21. Molecular basis of non-responsiveness to peroxisome proliferators: The guinea-pig PPARα is functional and mediates peroxisome proliferator-induced hypolipidaemia
22. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics
23. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
24. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids
25. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
26. Transcriptional induction of the fatty acid binding protein gene in mouse liver by bezafibrate
27. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial
28. 15-Deoxy-Δ12,14-PGJ2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways
29. Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation
30. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α
31. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
32. Review of clinical trials: Proving the lipid hypothesis
33. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia
34. Troglitazone action is independent of adipose tissue
35. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes
36. Epidemiology of triglycerides: A view from Framingham
37. Bayer decides to withdraw cholesterol lowering drug
38. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
39. Current, new and future treatments in dyslipidaemia and atherosclerosis
40. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor
41. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
42. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
43. Less extrahepatic induction of fatty acid β-oxidation enzymes by PPARα
44. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment
45. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
46. Evidence for a novel cardiac-enriched retinoid X receptor partner
47. Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; Ligand selectivity and agonist activation in the ppar family
48. Evidence that triglycerides are an independent coronary heart disease risk factor
49. Triglycerides: A risk factor for coronary heart disease
50. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
51. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
52. Retardation of coronary atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials
53. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
54. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1
55. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators
56. The PPARα-leukotriene B4 pathway to inflammation control
57. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
58. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice
59. The role of the peroxisome proliferator-activated receptor α (PPAR α) in the control of cardiac lipid metabolism
60. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
61. Statins: Intervention studies facts and perspectives (French)
62. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
63. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
64. Hypertriglyceridemia and the fibrate trials
65. Cerivastatin in the treatment of mixed hyperlipidemia: The RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment
66. CGP 43371 paradoxically inhibits development of rabbit atherosclerotic lesions while inducing extra-arterial foam cell formation
67. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia
68. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
69. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group
70. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism
71. Is cholesterol the major lipoprotein risk factor in coronary heart disease? - A Franco-Scottish overview
72. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group
73. Molecular mechanism of action of the fibrates (French)
74. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety
75. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions
76. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity
77. Regulation of lipid and lipoprotein metabolism by PPAR activators
78. Atherosclerosis. The road ahead
79. Familial hypercholesterolemia
80. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
81. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
82. Lipid management in patients at moderate risk for coronary heart disease: Insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
83. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions
84. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
85. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee
86. Micronized fenofibrate: A new fibric acid hypolipidemic agent
87. Predicting risk reduction of coronary disease in patients who are glucose intolerant: A comparison of treatment with fenofibrate and other lipid-modifying agents
88. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy
89. Inhibitors of platelet function in the prevention of arterial thrombosis
90. Critical evaluation of platelet-inhibiting drugs in thrombotic disease
91. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects
92. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III
93. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
94. Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor α down-regulate platelet-activating-factor receptor expression in human macrophages
95. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells
96. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27
97. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
98. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
99. Endothelin-1 is increased overlying atherosclerotic plaques in human arteries
100. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers
101. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting
102. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
103. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
104. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α
105. The role of fibric acid derivatives in the secondary prevention of coronary heart disease
106. Atherogenicity of triglyceride-rich lipoproteins
107. Mutation screening of the PPARα gene in type 2 diabetes associated with coronary heart disease
108. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
109. Effects of interferon-γ on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells
110. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter
111. Expression and function of PPARγ in rat and human vascular smooth muscle cells
112. Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus
113. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. PPARα fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression
114. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
115. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia
116. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
117. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
118. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium
119. The TNF and TNF receptor superfamilies: Integrating mammalian biology
120. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity
121. PPARγ: An essential regulator of adipogenesis and modulator of fat cell function
122. Addition of peroxisome proliferator-activated receptor α to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators
123. Regulating adipogenesis
124. Transcriptional regulation of the endothelin-1 gene by TNF-α
125. Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism
126. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
127. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
128. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells
129. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation
130. Impact of the peroxisome proliferator activated receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus
131. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice
132. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: Further insights from the veterans affairs high-density lipoprotein intervention trial
133. Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates
134. A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle
135. Advances in experimental dyslipidaemia and atherosclerosis
136. The role of PPAR-γ in macrophage differentiation and cholesterol uptake
137. Oestrogen and progesterone inhibit the stimulated production of endothelin-1
138. 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men
139. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner
140. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
141. Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet
142. The effect of activation of peroxisome proliferator-activated receptor gamma (PPARγ) on human monocyte function: PPARγ ligands do not inhibit tumor necrosis factor-γ release in human monocytic cell line THP-1
143. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia
144. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages
145. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
146. Bezafibrate reduces blood glucose in type 2 diabetes mellitus
147. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
148. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways
149. Peroxisome proliferator activated receptor-α expression in human liver
150. Evidence against the peroxisome proliferator-activated receptor α (PPARα) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription
151. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ
152. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
153. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
154. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia
155. 2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: The European Atherosclerosis Research Study II
156. Peroxisome proliferator-activated receptors, coactivators, and downstream targets
157. Biology of atherosclerotic plaque formation: Possible role of growth factors in lesion development and the potential impact of soy
158. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
159. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes
160. Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus
161. Relation of gemfibrozil treatment and lipid levels with major coronary events: A randomized controlled trial
162. Transcriptional regulation of adipogenesis
163. Atherosclerosis: Current understanding of mechanisms and future strategies in therapy
164. Cell biology of atherosclerosis
165. Atherosclerosis - An inflammatory disease
166. Triglycerides and coronary heart disease: Implications of recent clinical trials
167. Conclusions from the VA-HIT study
168. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group
169. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
170. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: Beneficial effects of bezafibrate treatment
171. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus
172. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart
173. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program
174. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group
175. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function
176. Thiazolidinediones: An update
177. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group
178. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men
179. Pioglitazone: Mechanism of action
180. Regulation of adipogenesis and energy balance by PPARγ and PGC-1
181. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels
182. Raising high-density lipoprotein cholesterol with niacin and fibrates: A comparative review
183. Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients
184. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
185. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
186. Mechanism of action of fibrates on lipid and lipoprotein metabolism
187. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
188. Lipid intervention trials in diabetes
189. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
190. Beyond LDL cholesterol reduction
191. A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial
192. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
193. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
194. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
195. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
196. Peroxisome proliferator-activated receptor-γ activation inhibits interleukin-1β-mediated platelet-derived growth factor-α receptor gene expression via CCAAT/enhancer-binding protein-δ in vascular smooth muscle cells
197. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
198. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor γ: Implications for cardiovascular disease
199. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
200. N-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes
201. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate
202. Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women
203. Do sphingoid bases interact with the peroxisome proliferator activated receptor α (PPAR-α)?
204. Molecular scanning of the human PPARa gene: Association of the L162v mutation with hyperapobetalipoproteinemia
205. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages
206. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
207. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids
208. Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease
209. Fibrates, dyslipoproteinaemia and cardiovascular disease
210. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity
211. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
212. 2 missense mutation
213. Extraperoxisomal targets of peroxisome proliferators: Mitochondrial, microsomal, and cytosolic effects. Implications for health and disease
214. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes
215. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
216. Characterization of a new form of inherited hypercholesterolemia: Familial recessive hypercholesterolemia